Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold shares in a pre-planned transaction. On April 30, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 shares of common stock in open-market trades at prices such as $579.51 and $570.76 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the transactions, Rothblatt holds 50,013 common shares directly and also has indirect ownership through family trusts and a spouse account, including 324,443 shares, 258,117 shares, 45,596 shares, 10,962 shares held by trusts, and 166 shares held by her spouse.
UNITED THERAPEUTICS Corp CFO James Edgemond exercised and sold shares in a planned transaction. On April 30, 2026, he exercised 10,000 stock options for Common Stock at a strike price of $135.42 per share and then sold 10,000 shares in a series of open-market trades at prices reported between $569.24 and $578.76 per share.
These actions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025. After the transactions, he directly owned 18,876 shares of United Therapeutics common stock.
Martine Rothblatt filed a Form 144 to sell 190,000 shares of common stock on 05/01/2026. The filing lists the method as an Exercise of Stock Options with cash proceeds and shows an aggregate figure of $108,556,500.00. The broker listed is Morgan Stanley Smith Barney LLC (New York).
The filing also enumerates multiple 10b5-1 sales of 9,500 shares on many dates in March–April 2026 and a separate 75-share sale on 03/13/2026. These prior sale entries show per-trade proceeds in the filing (examples include $5,430,339.25, $5,561,056.15, $40,271.25).
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open-market trades at prices ranging from about $565.10 to $574.31. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising up to 1,734,410 options expiring in March 2027 or December 31, 2026. After these transactions, she holds 50,013 common shares directly, additional common shares indirectly through various family trusts and her spouse, and 91,288 stock options remain outstanding.
Vanguard Capital Management reported beneficial ownership of 2,278,348 shares of United Therapeutics Corporation Common Stock, representing 5.19% of the class as of 03/31/2026. The filing shows Vanguard has sole voting power over 320,809 shares and sole dispositive power over 2,278,348 shares. The filing states these holdings include securities managed across Vanguard affiliates and funds.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at $146.03 per share and, on the same day, sold 9,500 shares in multiple open-market transactions around $565–$572 per share.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the trades, Rothblatt directly owns 40,513 common shares and also has additional indirect holdings through family trusts and a spouse account.
United Therapeutics Corporation calls a virtual 2026 annual shareholder meeting on June 26, 2026 to vote on electing 12 directors, an advisory “Say‑on‑Pay” resolution, approval of the 2026 Stock Incentive Plan, and ratification of Ernst & Young LLP as independent auditor.
The company highlights strong 2025 results, including 11% revenue growth, a 42% net income margin, 56% EBITDASO margin, and 38% total shareholder return, alongside $1.0 billion returned via an accelerated share repurchase. Management emphasizes its pay‑for‑performance design, with 91.1% of CEO pay and 83.6% of other named executive officer pay performance‑based, and its public benefit mission focused on pulmonary hypertension therapies, organ manufacturing, and clinical progress with ralinepag, nebulized Tyvaso for pulmonary fibrosis, and the UKidney xenotransplantation trial.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in multiple open-market trades at prices around $565–$572.42 per share.
The filing shows this exercise-and-sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which runs until either 1,734,410 stock options expiring on March 17, 2027 are exercised or until December 31, 2026. After these transactions, Rothblatt directly owns 50,013 shares of common stock, alongside additional indirect holdings through family trusts and a spouse account.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. On April 27, 2026, he exercised 10,000 stock options at $135.42 per share and sold 10,000 common shares in multiple open-market trades at weighted-average prices around $565–$572, under a Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, he directly holds 18,876 common shares and 52,500 stock options.